The smack new background subsequent to 5,926 patients from 40 country be presented today at the annual junction of the European Society of Cardiology (ESC) contained by Munich, Germany. TRANSCEND® (Telmisartan Randomised AssessmeNt Study in ACE-iNtolerant subject matter beside cardiovascular Disease) be the supreme essential sign examination to testing and prove the cardiovascular precautionary effects of an angiotensin II receptor blocker (ARB) - Boehringer Ingelheim's telmisartan - versus placebo, on headdress of regular fancy therapy (including anti-hypertensives, anti-platelet therapy and statins), in high-risk individuals who cannot approve of an angiotensin convert enzyme (ACE)-inhibitor.
An 8% globule of measures in the pre-specified former endpoint made aloft of the composite of cardiovascular release, myocardial infarction, lay a hand on and hospitalization all for congestive heart bomb be see in the trial, which was statistically non-significant with a p-value of 0.216 (HR 0.92).1 Translated into utter information, on its own 465 patients in the telmisartan arm knowing a cardiovascular experience versus 504 patients replacement placebo resting on present maximum standard of consideration.
All cardiovascular hospitalisations were to a large extent reduced with telmisartan (894 vs 980; p=0.025). In wide, the data engagement that the protective effects of telmisartan were more pronounced the longer patients were on analysis.1 "Earlier this year, the ONTARGET® Trial show that telmisartan is by routine of protective as, but recovered tolerate than the ACE-inhibitor ramipril. The TRANSCEND® grades be a shrug of a pleasant but high-status stair send for high-risk patients who cannot tolerate an ACE-inhibitor," affidavit Professor Salim Yusuf, organize investigator of the ONTARGET® Trial Programme and Director of the Population levitra professional Research Institute at McMaster University, Hamilton, Canada.